ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its Neuropathy Treatment Device; Expects Sales to Increase 30%

CHARLES TOWN, W.Va., Oct. 9 /PRNewswire/ -- ReBuilder Medical Technologies, Inc. today announced a contract with ETS, Inc of Albuquerque NM (http://www.etsnm.com) to manufacture an updated version of the ReBuilder System(R), the Professional Model 2407. ETS is an FDA-registered contract manufacturer for electronic device companies, including electronic glucose monitors, blood pressure cuffs and microwave ovens containing voice synthesizers to assist visually impaired diabetics.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )

For the past six months, ReBuilder Medical Technologies, Inc. and ETS have been in negotiations while ETS completed its research and development of the ReBuilder System(R) 2407 model, implementing valuable improvements for the device. The prototype of the newer model, which features larger knobs that are easier to adjust for those suffering from neuropathy, and a third treatment modality, has been approved, and ETS has now begun production, with the first units shipped to customers within the next 10 days.

The ReBuilder System(R) treats peripheral neuropathy, a side effect of diabetes, and has a success rate that tops 90%. It is also beneficial in treatment of restless leg syndrome (RLS). Providing service to diabetics suffering the most advanced symptoms will increase sales by 30% and as we penetrate the RLS market, we should see sales increasing over 45% per year for the next few years. These are patients who have become accustomed to dependence on others and are thrilled to be able to treat themselves in a way that is suitable for their unique circumstances," said Dr. Phillips.

About ReBuilder Medical Technologies, Inc.:

ReBuilder Medical Technologies, Inc. is a manufacturer of medical devices and innovative technologies founded by world-renowned medical device inventor David B. Phillips, Ph.D. The company's flagship product is its FDA registered ReBuilder System(R), used for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) that depend on prescription drugs with powerful side effects, the ReBuilder System(R) is a portable, battery-powered medical product that provides a unique, non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.

ReBuilder Medical Technologies, Inc. also manufactures the Phillips Molluscum Treatment System(TM) for treating the skin disease Molluscum Contagiosum which primarily affects children. This system uses its proprietary form of micronized amorphous silver ions to disable the molluscum pathogen without side effects. The company is currently performing research and development on a number of other products as well.

ReBuilder Medical Technologies, Inc. is located in Charles Town, WV. CEO, Dr. David Phillips, Ph.D. is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System, which is used for the early detection of breast cancer, and the AcuPen, a hand-held device that provides the benefits of acupuncture without the use of needles.

More information on ReBuilder Medical Technologies, Inc. and its products can be found at: http://www.rebuildermedical.com.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.

CONTACT: Daena Carter of ReBuilder Medical Technologies, Inc.,
+1-304-725-2202

Web site: http://www.etsnm.com/
http://www.rebuildermedical.com/